Gilbert Kliman Sells 5,000 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 5,000 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total value of $703,800.00. Following the transaction, the director directly owned 35,528 shares in the company, valued at approximately $5,000,921.28. The trade was a 12.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Glaukos Trading Down 1.5%

Shares of NYSE:GKOS opened at $140.06 on Wednesday. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $148.11. The stock’s fifty day moving average price is $118.35 and its 200-day moving average price is $112.54. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73. The company has a market cap of $8.23 billion, a P/E ratio of -42.70 and a beta of 0.94.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The company had revenue of $150.57 million for the quarter, compared to the consensus estimate of $137.00 million. During the same quarter in the prior year, the company earned ($0.22) earnings per share. Glaukos’s revenue was up 41.2% on a year-over-year basis. Sell-side analysts expect that Glaukos Corporation will post -0.57 earnings per share for the current year.

Institutional Trading of Glaukos

A number of hedge funds and other institutional investors have recently bought and sold shares of GKOS. Janus Henderson Group PLC increased its position in Glaukos by 77.2% in the first quarter. Janus Henderson Group PLC now owns 5,348,395 shares of the medical instruments supplier’s stock worth $575,844,000 after buying an additional 2,329,608 shares in the last quarter. Primecap Management Co. CA grew its position in shares of Glaukos by 49.8% during the fourth quarter. Primecap Management Co. CA now owns 3,376,928 shares of the medical instruments supplier’s stock worth $381,289,000 after purchasing an additional 1,123,140 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of Glaukos by 209.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,350,425 shares of the medical instruments supplier’s stock worth $152,476,000 after purchasing an additional 913,458 shares in the last quarter. Millennium Management LLC grew its position in shares of Glaukos by 75.3% during the fourth quarter. Millennium Management LLC now owns 1,609,699 shares of the medical instruments supplier’s stock worth $181,751,000 after purchasing an additional 691,289 shares in the last quarter. Finally, UBS Group AG grew its position in shares of Glaukos by 316.0% during the fourth quarter. UBS Group AG now owns 873,942 shares of the medical instruments supplier’s stock worth $98,677,000 after purchasing an additional 663,849 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Stifel Nicolaus set a $170.00 target price on Glaukos in a report on Thursday, April 30th. BTIG Research increased their target price on Glaukos from $131.00 to $141.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Citigroup increased their target price on Glaukos from $135.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, April 30th. JPMorgan Chase & Co. upped their price target on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Finally, Wall Street Zen upgraded Glaukos from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Glaukos currently has an average rating of “Moderate Buy” and an average target price of $144.42.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.